Updated: Aug 20
Cervical carcinoma is one of the most common diseases among women – with India accounting for around 16% of the total cervical cancer cases globally. Although the incidences have reduced over the years, cervical cancer is still one of the leading causes of cancer mortality, accounting for 17% of all cancer deaths among women aged between 30 and 69 years.
There are around five types of standard treatment protocols to treat Cervical Intraepithelial Neoplasia (CIN), involving Surgery or Conization, Radiation therapy, Chemotherapy, Targeted therapy and Immunotherapy, each having distinct advantages and disadvantages to the patient.
Thermocoagulation or Thermal coagulation method is slowly growing into a viable alternative treatment procedure, that can be used in the single-visit “screen-and-treat” approach, “see-and-treat” approach and in management of ectocervical CIN in cervical cancer control programs. The procedure is intended to conduct monopolar electrosurgical energy from the electrosurgical generator to target the tissue. This treatment protocol has various advantages, in that it is a portable device that uses minimal electricity and can provide a painless and affordable treatment to patients causing minimal adverse reactions and shorter recovery periods.
ZEPNURhealth has recently partnered with a US-based battery-powered manufacturer, that has designed the ThermocoagulatorTM - a reusable, handheld, battery-powered device that can help treat pre-cancerous cervical lesions in 20 seconds.
The device is designed according to WHO guidelines and recommendations for fighting the growing epidemic of cervical cancer and can be used in hospital and non-hospital rural healthcare locations. The device is also designed to perform low-power destruction of human pre-cancer cervical or other tissue with high temperatures by tissue contact with a heated probe tip. (See below Fig1: Technical specs of the ThermocoagulatorTM and Fig2: Parts of the ThermocoagulatorTM)
Figure 1: Technical Specs of the Thermocoagulator
Figure 2: Parts of the Thermocoagulator
A clinical research trial conducted on the device pooled data from five sites in Asia and South America for women treated for CIN with thermal coagulation from March 2010 to October 2015 and followed up within 6 - 12 months after treatment. Estimates of cure, adverse effects, or complications were presented as proportions. Bayesian models were used to assess factors affecting compliance with follow-up and cure rates.
Of the 1,626 women treated for CIN at baseline, 775 (48%) had follow-up evaluation. Attendance for follow-up increased with increasing education and CIN grade and was less likely to be among those aged ≥ 40 years. The estimates of the cure after thermal coagulation treatment were 88% (475/543) for CIN 1, 83% (113/137) for CIN 2 and 83% (79/95) for CIN 3 lesions. No serious adverse effects or complications were observed throughout the follow-up period for which hospitalization was required. (See more information in Fig3: Effect of Women Characteristics on CIN Cure Rates After Treatment With Thermal Coagulation)
Figure 3: Effect of women characteristics on CIN Cure Rates after treatment with Thermal Coagulation
To know more about the Thermocoagulator, or to see a demo of the product, get in touch with ZEPNURhealth (https://zepnurhealth.com/) (Call us on 1800 102 8348 or email us on email@example.com)
ZEPNURhealth is an online platform that assists hospitals, clinics, and diagnostic centers to manage their procurement. We essentially provide an integrated online-offline experience for the customer, by providing technical comparisons for different products and brands, overseeing price negotiations, and assisting customers through the entire procurement cycle, including after-sales service. We offer our services across medical and dental specialties to healthcare facilities, with a focus on the Southern Indian states.